PTO/SB/08a (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMEDICE.

	Undert	ne Paperwork Redu	uction Act of 1995, no	persons are requir	ed to respond to a collection of informat	tion unless it contains a valid OV	
	Substitut	o for form 1449/	A/PTO		Com	plete if Known	
					Application Number	10/584,998	
	INFO	RMATION	DISCLOSU	JRE	Filing Date	January 16, 2007	$\overline{}$
1	STAT	EMENT B	Y APPLICA	ANT	First Named Inventor	LEVY, Andrew	
1					Art Unit	1634	
	(us	e as many shee	ets as necessar,	0	Examiner Name		
Sheet		1	of	7	Attorney Docket Number	P-7339-US1	7

		\ I	J.S. PATENT I	DOCUMENTS	
Examiner Initials*	Cite No. 1	Document Number  Number-Kind Code <sup>2 (f known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Igures Appear
		US-			
		US-		/	
		US-		1	
		US-			
		US-			

		FOREIGN PA	TENT DOCK	MENTS		
Examiner Initials*	Cite, No.	Foreign Patent Document  Country Code <sup>9</sup> Number <sup>4</sup> Kind Code <sup>9</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	Α	WO-9001069	1990	SEGEV, at al		
	В	WO98/37419	1998	DELANGHE		
	С	WO 2004/060135 /2	22 JULY 2004			
	D	WO 01/80712	01 NOVEMBER 2001			
					<b></b>	
	-				\	
-		/			<del></del>	
		/				- :
- Formation	$\overline{}$		•	Date	$\overline{}$	
Examiner Signature				Considered	/	

EXAMPLE Initial if reference considered, whether or not obtains is in conformance with MPEP 609. Draw line through chation if not in combinance and not considered include copy of the form with next communication to applicant. Applicants unique chation designation number (optional). See Kinds Case of 1969 P places to Comments at wine unique power of the Property of

The extension of internation is required by 3° CFF 197 and 1.98. The information is required to defair or retain is brond by the public which is to fit part by the USFO to proceed an application. Confidentially in governed by \$6.15.8. C.122 and 3° CFF 11.4. This condection is selfcrated to the 2-but so complete modeling splinering propaging and salveilling the completed application from to the USFIO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete the form and/or suggestions for reducing the burders, should be sent to the Child Information Office, US-Parest and Trademark Office. US. Department of Commence, P.O. Box 1450, Alexandria, VA. 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissions for Patients, P.O. Box 1450, Alexandria, VA. 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissions for Patients, P.O. Box 1450, Alexandria, VA. 22313-1450.

PTO/SB/08b (07-05)

Approved for use through 06/30/2006. OMS 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Unide	a tric r apartion in	DECEMBER OF 193	s, no persons are re	squired to respond to a concessor or and	THE CHIEF CONTROL OF THE FIRST	
Substit	ute for form 144	9B/PTO		Complete if Known		
				Application Number	10/584,998	
INFO	RMATION	DISCLOS	URE	Filing Date	January 16, 2007	
STA.	TEMENT E	BY APPLIC	ANT	First Named Inventor	LEVY, Andrew	
				Art Unit	1634	
(use as many sheets as necessary)				Examiner Name		
Sheet	2	of	7	Attorney Docket Number	P-7339-US1	

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>		
	E	BUHLIN K et al. "Risk factors for cardiovascular disease in patients with periodontitis." Eur Heart J. 2003 Dec;24(23):2099-107.			
	F	DE BACQUER D et al. "Haptoglobin polymorphism as a risk factor for coronary heart disease mortality. " Atherosclerosis. 2001 Jul;157(1):161-6.			
	G	HONG SH et al. "Haptoglobin polymorphism in Korean patients with cardiovascular diseases." Hum Hered. 1997 Sep-Oct;47(5):283-7.			
	н	YUSUF S et al. "Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators." N Engl J Med. 2000 Jan 20;342(3):154-60.			
	LIND P et al. "Risk of myocardial infarction in relation to plasma levels of homocysteine and inflammation-sensitive proteins: a long-term nested case-control study." Angiology. 2003 Jul-Aug;54(4):401-10.  NISHIKAWA T et al. "Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage." Nature. 2000 Apr 13;404(6778):787-90.				
	к	OHGAMI N et al. "CD36, serves as a receptor for advanced glycation endproducts (AGE)." J Diabetes Complications. 2002 Jan-Feb;16(1):56-9.			
	L	STAMLER J et al. "Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial." Diabetes Care. 1993 Feb:18(2):434-44.			
	STEINEERG D. (1997) "Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem; 272-20963-6  WILLIAMS, et al., (1992) "Dietary vitamin E and the attenuation of early lesion development in modified Watanabe rabbits." Atherosclerosis 1992 June; 94:153-159.				
BROWN BG et al. "Simvastatin and niacin, antioxidant vitamins, or the combination of the prevention of coronary disease." N Engl J Med. 2001 Nov 29;345(22):1583-92.					

and adventure or an above to be an about the second		

EXAMINER: initial if reference considered, whether or or classon is in conformance with MPEP 909. Draw line strough distation if not in conformance and not considered, whether or include copy of this form with next communication to applicant.

Signature

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Considered

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached

Proceedings of information is required to market by common by pages of the collection of information is required by ST CFR 137 and 138. The elboration is required to detain or retain a benefit by the public which is to file (and by the USPT Do process) an application. Common the process of the process of

	ute for form 144		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Complete if Known		
				Application Number	10/584,998	
INFO	RMATION	DISCLOS	URE	Filing Date	January 16, 2007	
STA	TEMENT E	BY APPLIC	ANT	First Named Inventor	LEVY, Andrew	
				Art Unit	1634	
(use as many sheets as necessary)				Examiner Name		
Sheet	3	of	7	Attorney Docket Number	P-7339-US1	

		NON PATENT LITERATURE DOCUMENTS			
xaminer nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>		
		GISSI, Lancet 1999; 354:4477-55			
	Р				
	Q	HODIS HN et al. "Alpha-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis: the Vitamin Atherosclerosis Prevention Study (VEAPS). "Circulation. 2002 Sep 17:106(12):1453-9.			
	R	JIANG XC et al. "Phospholipid transfer protein deficiency protects circulating lipoproteins from oxidation due to the enhanced accumulation of vitamin E."J Biol Chem. 2002 Aug 30:277(35):31850-6. Epub 2002 Jun 24.			
	s	LEVY AP et al. "Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study." J Am Coll Cardiol. 2002 Dec 4;40(11):1984-90.			
	т	MARCHIOLI R et al. "Antioxidant vitamins and prevention of cardiovascular disease: epidemiological and clinical trial data." Lipids. 2001;36 Suppl:S53-63.			
	U	FRANK MB et al. "The Kozak sequence polymorphism of platelet glycoprotein  balpha and risk of nonfatal myocardial infarction and nonfatal stroke in young  women." Blood. 2001 Feb 15:97(4):875-9.			
	v	STEINBERG D et al. "Is the oxidative modification hypothesis relevant to human atherosclerosis?" Do the antioxidant trials conducted to date refute the hypothesis?" Circulation. 2002 Apr 30;105(17):2107-11.			
	w	UK Prospective Study Group Diab Care 1998; 21: 1271-1277			
	WATERS DD et al. "Effects of hormone replacement therapy and antioxidant vitamin xupplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial." JAMA. 2002 Nov 20;288(19):2432-40.				
	Υ	WITZTUM JL et al. "The oxidative modification hypothesis of atherosclerosis: does it			
	BARANY F et al. "The ligase chain reaction in a PCR world." PCR Methods Appl.  Z 1991 Aug;1(1):5-16.				

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Signature

Considered

The collection of information is required to studied by 37 CPR 1.97 and 1.98. The information is required to detain or retain a benefit by the public which is life (and by the LSPP Os proceed an application. Confidentially is operand by 58 U.S. PC CPR 1.97 and 1.98. The information of required to detail not retain a benefit by the public which is life (and by the LSPP Os proceed an application. Confidentially is operand by 58 U.S. PC CPR 1.07 CPR 1.14. The collection is estimated to take 2 hours to complete, including an around following the public required to complete the form and/or suggestions for reducing the burdent, should be sent to the CRI the firmation follow; U.S. Petent and Trademank, Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Commissioner for Petenting P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

	ute for form 144		, , , , , , , , , , , , , , , , , , , ,	Complete if Known		
				Application Number	10/584,998	
INFO	RMATION	DISCLOS	URE	Filing Date	January 16, 2007	
STA	TEMENT E	BY APPLIC	ANT	First Named Inventor	LEVY, Andrew	
				Art Unit	1634	
(use as many sheets as necessary)				Examiner Name		
Sheet	4	of	7	Attorney Docket Number	P-7339-US1	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	АА	BARANY F. "Genetic disease detection and DNA amplification using cloned thermostable ligase." Proc Natl Acad Sci U S A. 1991 Jan 1;88(1):189-93.	
	АВ	BROWN BG et al. "Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease." N Engl J Med. 2001 Nov 29;345(22):1583-92.	
	AC	FAHY E et al. "Self-sustained sequence replication (3SR); an isothermal transcription-based amplification system alternative to PCR." PCR Methods Appl. 1991 Aug;1(1):25-33.	
	AD	GUATELLI JC et al. "Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication." Proc Natl Acad Sci U S A. 1990 Mar;8(5):1874-8.	
	AE	MULLIS KB. "The polymerase chain reaction in an anemic mode: how to avoid cold oligodeoxyribonuclear fusion." PCR Methods Appl. 1991 Aug;1(1):1-4	
	AF	GOGS JA et al. "Detection of single base mismatches of thymine and cytosine residues by potassium permanganate and hydroxylamine in the presence of letralkylammonium salts." Nucleic Acids Res. 1990 Dec 11;18(23):6807-14.	
	AG	Wu DY et al. "The ligation amplification reaction (LAR)amplification of specific DNA sequences using sequential rounds of template-dependent ligation." Genomics. 1999 May:4(4):560-9.	
	АН	Barlow and Lehrach, Trends Genet., 3:167 (1987)	
	AI	CONNER BJ et al. "Detection of sickle cell beta S-globin allele by hybridization with synthetic oligonucleotides." Proc Natl Acad Sci U S A. 1983 Jan;80(1):278-82.	
	AJ	FARR CJ et al. "Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes." Proc Natl Acad Sci U S A. 1998 Mar;85(5):1829-33.	
	AK	LEVY AP et al. "The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes." Diabetes Care. 2004 Nov:27(11):2767.	

Signature		Considered
	A company of the comp	

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered include copy of this form with next communication to applicant.

Examiner

Date

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required to market by common by passes of the collection of the colle

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitu	ite for form 144	9B/PTO		Complete if Known	
				Application Number	10/584,998
INFO	RMATION	DISCLOS	URE	Filing Date	January 16, 2007
STA	FEMENT E	BY APPLIC	ANT	First Named Inventor	LEVY, Andrew
				Art Unit	1634
(us	e as many she	ets as necessa	ry)	Examiner Name	
Sheet	5	of	7	Attorney Docket Number	P-7339-US1

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, div and/or country where publisher.	T <sup>2</sup>
	AL	KWOK S et al. "Effects of primer-template mismatches on the polymerase chain reaction: human immunodeficiency virus type 1 model studies." Nucleic Acids Res. 1990 Feb 25;18(4):999-1005.	
	AM	LYONS J et al. "Two G protein oncogenes in human endocrine tumors." Science. 1990 Aug 10;249(4969):855-9.	
	AN	PERLMAN PS et al. "Mobile introns and intron-encoded proteins." Science. 1989 Dec 1;246(4934):1106-9.	
	AO	URDEA MS et al. "A novel method for the rapid detection of specific nucleotide sequences in crude biological samples without blotting or radioactivity; application to the analysis of hepatitis B virus in human serum." Gene. 1987;61(3):253-64.	
	AP	VOGELSTEIN B et al. "Genetic alterations during colorectal-tumor development." N Engl J Med. 1988 Sep 1;319(9):525-32.	
	AQ	ABRAMS ES et al. "Comprehensive detection of single base changes in human genomic DNA using denaturing gradient gel electrophoresis and a GC clamp." [Genomics. 1990 Aug;7(4):463-75.	
	AR	BØRRESEN AL et al. "Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations." Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8405-9.	
	AS	HAYASHI K. "PCR-SSCP: a simple and sensitive method for detection of mutations in the genomic DNA." PCR Methods Appl. 1991 Aug;1(1):34-8.	
	АТ	LERMAN LS et al. "Computational simulation of DNA melting and its application to denaturing gradient gel electrophoresis." Methods Enzymol. 1987;155:482-501.	
	AU	LIU Q et al. "Parameters affecting the sensitivities of dideoxy fingerprinting and SSCP." PCR Methods Appl. 1994 Oct;4(2):97-108.	
	AV	ORITA M et al. "Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction." Genomics. 1989 Nov:5(4):874-9.	

		·
Examiner	Date	
Signature	Considered	

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. EAVAINTEE: make it removes to construct the construction to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

reposals a unique cultural recognition in manner (procurs), appearant to it places a chrock man. Never Lington stratugate intrastance for the collection of richmarkers in required to challen or retain a benefit by the public which is to fire (and by the USPTO) to poccess) an application. Confidentially is governed by \$8.0 LSC 2 and \$7.0PH. 1.1h. The oblection is estimated to take 2 hours to complete, including a contract of the confidential or retain a benefit by the public which is to fire (and by the USPTO) to poccess) an application. Confidentially is governed by \$8.0 LSC 2 and \$7.0PH. 1.1h. The oblection is estimated to take 2 hours to complete, including a contract of the require to complete the form and/or suggestions for reducing fits burdent, should be sent to the Colle fifthermation Office, US 2 Pearst and Trademark Office. U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Commissions for Petents, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Commissions for Petents, P.O. Box 1450, Alexandria, VA 22313-1450.

	ute for form 144		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Complete if Known	
				Application Number	10/584,998
INFO	RMATION	DISCLOS	URE	Filing Date	January 16, 2007
STA	TEMENT E	Y APPLIC	CANT	First Named Inventor	LEVY, Andrew
				Art Unit	1634
(u:	se as many she	ets as necessa	iry)	Examiner Name	
Sheet	6	of	7	Attorney Docket Number	P-7339-US1

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	AW	SCHOLZ RB et al. "Rapid screening for Tp53 mutations by temperature gradient gel electrophoresis: a comparison with SSCP analysis."Hum Mol Genet. 1993 Dec:2(12):2155-8.	
	AX	SHEFFIELD VC et al. "Attachment of a 40-base-pair G + C-rich sequence (GC- clamp) to genomic DNA fragments by the polymerase chain reaction results in improved detection of single-base changes."Proc Natl Acad Sci U S A. 1989 Jan:86(1):232-6.	
	AY	SMITH FI et al. "Novel method of detecting single base substitutions in RNA molecules by differential melting behavior in solution." Genomics. 1988   Oct;3(3):217-23.	
	AZ	WARTELL RM et al. "Detecting base pair substitutions in DNA fragments by temperature-gradient gel electrophoresis."Nucleic Acids Res. 1990 May 11;18(9):2699-705.	
	ва	CAMPO, et al, Cardiovasc Drug Rev 1997; 15: 157-173	
	вв	KITA T et al. "Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia." Proc Natl Acad Sci U S A. 1987 Aug;84(16):5928-31.	
	вс	MAK IT et al. "Protective effects of dihydropyridine Ca-blockers against endothelial cell oxidative injury due to combined nitric oxide and superoxide." Pharmacol Res. 2002 Jan;45(1):27-33.	
	BD	Meng CQ et al. "Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis." Bioorg Med Chem Lett. 2002 Sep 16;12(18):2545-8.	
	BE	SAGACH, et al, Pharma Res 202; 45: 435-439	
	BF	YOSHIDA N et al. "Inhibitory effect of a novel water-soluble vitamin E derivative on atherosclerosis in rabbits." Atherosclerosis. 2002 May;162(1):111-7.	
	ВG	BLUM S et al. "Haptoglobin genotype determines myocardial infarct size in diabetic mice." J Am Coll Cardiol. 2007 Jan 2;49(1):82-7. Epub 2006 Dec 13.	

	,~	·· · · · ·	
Examiner Signature		Date Considered	

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered include copy of this form with next communication to applicant.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Proceedings of information is required to office the collection of information is required by 37 CFR 197 and 138. The information is required to obtain a brenist by the public which is to file (and by the USPTO) to proceed an application. Confidentially is governed by 58 USE 20 at 37 CPR 114. The oblection is estimated to take 2 hours to compete, including a confidential application of the confidential applicat

PTO/SB/08b (07-05) Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE pond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO					Complete if Known			
					Application Number	10/584,998		
INF	ORM	MATION	DISCLOS	SURE	Filing Date	January 16, 2007		
\ ST.	ATEN	MENT E	BY APPLIC	CANT	First Named Inventor	LEVY, Andrew	$\overline{}$	
					Art Unit	1634	/	
	(use as	many she	ets as necess	ary)	Examiner Name			
Sheet	X	7	of	7	Attorney Docket Number	P-7339-US1		
	1			•	•			
					ITERATURE DOCUMEN			
Examiner Initials*	Cite	iten (bo	name of the ar ok, magazine, j	ournal, serial, sy	AL LETTERS), title of the article imposium, catalog, etc.), date, po city and/or country where publish	age(s), volume-issye number(s),	T <sup>2</sup>	
	вн				Evaluation Study Investig			
	ВІ	Subgro Haptog 21, 200	up Of Middle lobin 2-2 Ge 7	-Aged Individual notype; Journ	ementation Reduces Card dual With Both Type 2 Dia nal Of The American Hear	betes Mellitus And The t Association November		
	ВЈ	SUPPL JUNE 2		EUROPEAN	SEARCH REPORT IS	JED IN EP 04 79 9315;		
	вк	OFFICE ACTION ISSUED IN CN 2003801180094/8; JUNE 5, 2009						
	BL				n polymorphism and perip Aug;145(2):287-92.	heral arterial occlusive		
	вм	and sus 3:92(11	ceptibility to	diabetic card	rrivined heterogeneity in h diovascular disease." Circ May 19	Res. 2003 Jun		
	LEVY AP et al. "The effect of vitamin the apy on the progression of coronary a BN atherosclerosis varies by haptoglotin type to postmenopausal women." Diabe Care. 2004 Apr:27(4):925-30.					ession of coronary artery usal women." Diabetes		
			_/			\		
		-/-			1			
Examiner Signature	٠,	/			Date Considered			

Under the Paperwork Reduction Act of 1995, no persons are requ

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

<sup>\*</sup> EXAMINER: Initia reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance d not considered Include copy of the form with next communication to applicant.

que citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached Applicant's u is colors, of information is required by 37 CFR1 157 and 158. The information is required to debation or states a complex by the public which is to help of PTO of proceed in regime projection. Confederable, it is proved by 55 U.S. of 22 and 57 CFR1 114. The reconstruction is entered by the public which is to help of the public incomplex of the property of the prop USPTO to including gatheri